LTIP828A - Nucleic acid fragment which codes for human proapolipoprotein a-1 - Google Patents

Nucleic acid fragment which codes for human proapolipoprotein a-1

Info

Publication number
LTIP828A
LTIP828A LTIP828A LTIP828A LTIP828A LT IP828 A LTIP828 A LT IP828A LT IP828 A LTIP828 A LT IP828A LT IP828 A LTIP828 A LT IP828A LT IP828 A LTIP828 A LT IP828A
Authority
LT
Lithuania
Prior art keywords
codes
proapolipoprotein
nucleic acid
acid fragment
sequence
Prior art date
Application number
LTIP828A
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of LTIP828A publication Critical patent/LTIP828A/en
Publication of LT3600B publication Critical patent/LT3600B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides recombinant DNA sequences comprising a sequence which codes for human proapolipoprotein A-I wherein part of the natural coding sequence has been replaced by a DNA fragment coding for the same amino acids but consisting of a different nucleotide sequence such as to reduce or prevent formation of hairpins, cloning and expression vectors containing these DNA sequences, cell cultures or microorganisms transformed with these expression vectors and processes using the same for the production of proapolipoprotein A-I.
LTIP828A 1987-05-28 1993-08-03 Nucleic acid fragment which codes for human proapolipoprotein a-i LT3600B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (2)

Publication Number Publication Date
LTIP828A true LTIP828A (en) 1995-02-27
LT3600B LT3600B (en) 1995-12-27

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP828A LT3600B (en) 1987-05-28 1993-08-03 Nucleic acid fragment which codes for human proapolipoprotein a-i

Country Status (33)

Country Link
US (1) US5059528A (en)
EP (1) EP0293357B1 (en)
JP (1) JP2634193B2 (en)
KR (1) KR970000808B1 (en)
CN (1) CN1031892C (en)
AT (1) ATE89006T1 (en)
AU (1) AU615654B2 (en)
CA (1) CA1323851C (en)
CY (1) CY1809A (en)
CZ (1) CZ283648B6 (en)
DD (1) DD291093A5 (en)
DE (1) DE3880739T2 (en)
DK (1) DK175686B1 (en)
EG (1) EG19101A (en)
ES (1) ES2054878T3 (en)
FI (1) FI100056B (en)
GB (1) GB8712540D0 (en)
HK (1) HK137794A (en)
HU (1) HU204562B (en)
IE (1) IE62422B1 (en)
IL (1) IL86480A (en)
LT (1) LT3600B (en)
LV (1) LV5288A3 (en)
NO (1) NO179253C (en)
NZ (1) NZ224808A (en)
PL (1) PL158064B1 (en)
PT (1) PT87562B (en)
RU (1) RU2009198C1 (en)
SG (1) SG131594G (en)
SK (1) SK279166B6 (en)
SU (1) SU1834904A3 (en)
UA (1) UA19765A (en)
ZA (1) ZA883824B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (en) * 1987-09-18 1997-04-30 三菱化学株式会社 Method for producing human proapolipoprotein AI-like protein
DE68917379T2 (en) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Process for the production of proteins similar to natural human apolipoprotein-E.
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (en) * 1989-04-20 1991-09-20 Cesare Sirtori EXPRESSION OF APOLIPOPROTEIN AI AND APOLIPOPROTEIN AI-MILAN IN YEAST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE APOLIPOPROTEINS.
WO1992009698A1 (en) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
DE69115926T2 (en) * 1990-11-30 1996-05-30 Monoclonetics Int METHOD FOR DIAGNOSING CHRONIC LOW BACK PAIN AND NECK PAIN
SE9500778D0 (en) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (en) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (en) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (en) * 1999-06-04 2002-04-01 장인순 Duct type spacer grid with swirl flow vane in nuclear fuel assembly
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AU2002232642B2 (en) * 2000-12-12 2007-02-01 Lexicon Pharmaceuticals, Inc. Novel human kinases and uses thereof
KR100560102B1 (en) * 2004-06-25 2006-03-13 한국생명공학연구원 Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
SG10201901089TA (en) 2008-11-10 2019-03-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
KR101835889B1 (en) 2009-05-06 2018-03-08 큐알엔에이, 인크. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
HUE056773T2 (en) 2009-06-10 2022-03-28 Arbutus Biopharma Corp Improved lipid formulation
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
IL300109A (en) 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN110123830A (en) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
RU2017126088A (en) 2011-02-07 2019-01-31 Серени Терапеутикс Холдинг С.А. Lipoprotein complexes and their preparation and use
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
CN111593051A (en) * 2013-05-01 2020-08-28 Ionis制药公司 Compositions and methods
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
EP3533872A4 (en) * 2016-10-27 2020-09-09 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Apomers
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (en) 2021-04-15 2023-10-26 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions.
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (en) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd Electric fan
BE901119A (en) 1984-11-23 1985-03-15 Wallone Region PROCESS FOR THE PREPARATION OF VECTOR PLASMIDS CAPABLE OF TRANSFORMING A BACTERIAL HOST ESCHERICHIA COLI AND OF PROMOTING AND CONTROLLING THE EXPRESSION OF HETEROLOGOUS DNA IN IT.
ATE89314T1 (en) 1985-02-13 1993-05-15 Scios Nova Inc HUMAN METALLOTHIONEIN II PROMOTOR IN MAMMALIAN EXPRESSION SYSTEMS.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
EP0239631A4 (en) 1985-10-04 1989-01-12 Biotech Res Partners Ltd Recombinant apolipoproteins and methods.
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
WO1988003175A1 (en) * 1986-10-29 1988-05-05 Biotechnology Research Partners, Ltd. Apoai-ciii-aiv, apoaii, apob, apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
RU2009198C1 (en) 1994-03-15
CZ363888A3 (en) 1998-02-18
FI882456A0 (en) 1988-05-25
PT87562B (en) 1992-09-30
EP0293357B1 (en) 1993-05-05
DE3880739D1 (en) 1993-06-09
DK175686B1 (en) 2005-01-17
LT3600B (en) 1995-12-27
CA1323851C (en) 1993-11-02
AU1672388A (en) 1988-12-01
ES2054878T3 (en) 1994-08-16
NO882341L (en) 1988-11-29
JP2634193B2 (en) 1997-07-23
JPS6416589A (en) 1989-01-20
NO882341D0 (en) 1988-05-27
KR970000808B1 (en) 1997-01-20
IE62422B1 (en) 1995-02-08
NO179253B (en) 1996-05-28
DD291093A5 (en) 1991-06-20
KR880014110A (en) 1988-12-22
CZ283648B6 (en) 1998-05-13
NO179253C (en) 1996-09-04
PL272698A1 (en) 1989-03-06
LV5288A3 (en) 1993-10-10
CN1031892C (en) 1996-05-29
UA19765A (en) 1997-12-25
AU615654B2 (en) 1991-10-10
SU1834904A3 (en) 1993-08-15
HK137794A (en) 1994-12-16
IE881597L (en) 1988-11-28
DK289688D0 (en) 1988-05-27
DK289688A (en) 1988-11-29
CY1809A (en) 1995-10-20
DE3880739T2 (en) 1993-08-19
SK363888A3 (en) 1998-07-08
EP0293357A1 (en) 1988-11-30
NZ224808A (en) 1990-01-29
CN88103118A (en) 1988-12-14
FI882456A (en) 1988-11-29
US5059528A (en) 1991-10-22
EG19101A (en) 1994-09-29
HUT47153A (en) 1989-01-30
PL158064B1 (en) 1992-07-31
PT87562A (en) 1989-05-31
HU204562B (en) 1992-01-28
SK279166B6 (en) 1998-07-08
FI100056B (en) 1997-09-15
IL86480A (en) 1992-08-18
ATE89006T1 (en) 1993-05-15
GB8712540D0 (en) 1987-07-01
SG131594G (en) 1995-01-13
ZA883824B (en) 1989-02-22
IL86480A0 (en) 1988-11-15

Similar Documents

Publication Publication Date Title
LTIP828A (en) Nucleic acid fragment which codes for human proapolipoprotein a-1
NO177433C (en) DNA Vector for Expression of Desulfatohirudin in Yeast or E.coli and Method of Preparation of Desulfatohirudin and Salts thereof
DE3586189D1 (en) QUANTITY AND METHOD FOR PRODUCING RECOMBINED PRODUCTS IN LARGE YIELD.
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
ZA200006041B (en) Nucleotide sequences coding for the export of branched-chain amino acids, process for the isolation thereof and use thereof.
NO177570B (en) Process for the preparation of peptides with fibronectin binding properties, microorganism and DNA sequence encoding peptides with fibronectin binding properties
ATE166390T1 (en) ANTI-CAT IMMUNODEFICIENCY VIRUS (FIV) VACCINES
ATE43139T1 (en) GAMMA INTERFERON CLONING AND EXPRESSION VECTORS, TRANSFORMED BACTERIA AND METHODS OF GAMMA INTERFERON PRODUCTION.
FR2792651A1 (en) New nucleotide sequences isolated from Pyrococcus abyssi encode proteins useful in industry
DK27097A (en) Minactivin and its method of preparation
ES8705921A1 (en) Production of human somatomedin c.
ATE188997T1 (en) CLONING OF MALARIA-SPECIFIC DNA SEQUENCES: ISOLATION OF THE GENE FOR THE 140 KD PROTEIN
DE69636737D1 (en) NEW IMMUNOREGULATORY PROTEIN LST-1
TH5997EX (en) Human reproduction of the protein A-I by expression of the genetic code.

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: 20010321 * MINISTERIE DE LA REGION WALLONNE,BE

MM9A Lapsed patents

Effective date: 20020803